Research Article
Virtual screening approach for the discovery of selective 5α-reductase type II inhibitors for benign prostatic hyperplasia treatment
Published Online:13 Nov 2023https://doi.org/10.4155/fmc-2023-0065
Abstract
Background: 5α-Reductase type II (5αR2) inhibition is a promising strategy for benign prostatic hyperplasia treatment. A computational approach including virtual screening, ligand-based 3D pharmacophore modeling, 2D quantitative structure–activity relationship and molecular docking simulations were adopted to develop novel inhibitors. Results: Hits were first filtered via the validated pharmacophore and 2D quantitative structure–activity relationship models. Docking on the recently determined cocrystallized structure of 5αR2 showed three promising hits. Visual inspection results were compared with finasteride ligand and dihydrotestosterone as reference, to explain the role of binding to Glu57 and Tyr91 for 5αR2 selective inhibition. Conclusion: Alignment between Hit 2 and finasteride in the binding pocket showed similar binding modes. The biological activity prediction showed antitumor and androgen targeting activity of the new hits.
Graphical abstract
Papers of special note have been highlighted as: •• of considerable interest
References
- 1. . Discovery of novel 5α-reductase type II inhibitors by pharmacophore modelling, virtual screening, molecular docking and molecular dynamics simulations. Mol. Simul. 41(4), 287–297 (2015).
- 2. . An overview on 5α-reductase inhibitors. Steroids 75(2), 109–153 (2010).
- 3. 19-Nor-10-azasteroids: a novel class of inhibitors for human steroid 5α-reductases 1 and 2. J. Med. Chem. 40, 1112–1129 (1997).
- 4. . The effect of 5 α-reductase inhibitors on erectile function. J. Androl. 29, 514–523 (2008).
- 5. . Trends in the development of new drugs for treatment of benign prostatic hyperplasia. Curr. Med. Chem. 13, 3395–3416 (2006).
- 6. . Benign prostatic hyperplasia. Lancet 361, 1359–1367 (2003).
- 7. Novel 5α-reductase inhibitors: synthesis, structure−activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J. Med. Chem. 49, 748–759 (2006).
- 8. . Complications of transurethral resection of the prostate (TURP) – incidence, management, and prevention. Eur. Urol. 50, 969–980 (2006).
- 9. . Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases. Proc. Natl Acad. Sci. 87, 3640–3644 (1990).
- 10. . The enzyme and inhibitors of 4-ene-3-oxosteroid 5α-oxidoreductase. Steroids 60, 430–441 (1995).
- 11. . Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate 57, 134–139 (2003).
- 12. A new look at the 5α-reductase inhibitor finasteride. CNS Drug. Rev. 12, 53–76 (2006).
- 13. The effect of finasteride in men with benign prostatic hyperplasia. N. Engl. J. Med. 327, 1185–1191 (1992).
- 14. FK143, a novel nonsteroidal inhibitor of steroid 5α-reductase: (2) in vivo effects on rat and dog prostates. J. Steroid Biochem. Mol. Biol. 52, 365–373 (1995).
- 15. 4-(1-Benzoylindol-3-yl) butyric acids and FK143: novel nonsteroidal inhibitors of steroid 5α-reductase (II). Chem. Pharm. Bull. (Tokyo) 47, 481491 (1999).
- 16. Biphenyls as surrogates of the steroidal backbone. Part 2: discovery of a novel family of non-steroidal 5-α-reductase inhibitors. Bioorg. Med. Chem. Lett. 11, 1713–1716 (2001).
- 17. . Cyclohex-1-ene carboxylic acids: synthesis and biological evaluation of novel inhibitors of human 5α reductase. Arch. Pharm. 336, 31–38 (2003).
- 18. . The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Adv. Urol. 2012, 978531 (2012).
- 19. . Consequences of steroid-5α-reductase deficiency and inhibition in vertebrates. Gen. Comp. Endocrinol. 290, 113400 (2020).
- 20. . 5α-Reductase: history and clinical importance. Rev. Urol. 6(Suppl. 9), S11–S21 (2004).
- 21. . Steroid 5 alpha-reductase inhibitors targeting BPH and prostate cancer. J. Steroid Biochem. Mol. Biol. 125, 32–38 (2011).
- 22. . Prostate cancer prevention with 5-alpha reductase inhibitors: concepts and controversies. Curr. Opin. Urol. 28, 42–45 (2018).
- 23. . Chemical mechanism of the covalent modification of 5. alpha.-reductases by finasteride as probed by secondary tritium isotope effects. J. Am. Chem. Soc. 117, 2369–2370 (1995).
- 24. Mechanism-based inhibition of human steroid 5α-reductase by finasteride: enzyme-catalyzed formation of NADP− dihydrofinasteride, a potent bisubstrate analog inhibitor. J. Am. Chem. Soc. 118(10), 2359–2365 (1996).
- 25. Androgen sensitivity gateway to COVID-19 disease severity. Drug Dev. Res. 81(7), 771–776 (2020).
- 26. Androgen signalling regulates SARS-CoV-2 receptor levels and is associated with severe COVID-19 symptoms in men. Cell Stem Cell 27(6), 876–889 (2020).
- 27. . Inhibition of human steroid 5β-reductase (AKR1D1) by finasteride and structure of the enzyme-inhibitor complex. J. Biol. Chem. 284, 19786–19790 (2009).
- 28. . Discovery of a novel hybrid from finasteride and epristeride as 5α-reductase inhibitor. Bioorg. Med. Chem. Lett. 21, 475–478 (2011).
- 29. . An unusual case of hermaphroditism-A 46, XX/69, XXY chimera. J. Pediatr. Endocrinol. Metab. 17, 905–908 (2004).
- 30. Structure of human steroid 5α-reductase 2 with the anti-androgen drug finasteride. Nat. Commun. 11(1), 1–11 (2020).
- 31. Way2drug. www.way2drug.com/passtargets/
- 32. . Strategies for database mining and pharmacophore development. In: Pharmacophore Perception, Development, and Use in Drug Design, IUL BIotechnology Series. Güner OF (Ed.). International University Line, La Jolla, CA, USA, 213–236 (2000).
- 33. . Potent BACE-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies. BMC Bioinform. 12, 1–11 (2011).
- 34. . ACE inhibitors hypothesis generation for selective design, synthesis and biological evaluation of 3-mercapto-2-methyl-propanoyl-pyrrolidine-3-imine derivatives as antihypertensive agents. Bioorg. Med. Chem. 17(10), 3739–3746 (2009).
- 35. National Cancer Institute. The NCI transcriptional pharmacodynamics workbench. https://tpwb.nci.nih.gov
- 36. National Cancer Institute. Downloadable structure files of NCI open database compounds. https://cactus.nci.nih.gov/download/nci/
- 37. . Design and synthesis of new tetrazolyl- and carboxy-biphenylylmethyl-quinazolin-4-one derivatives as angiotensin II AT1 receptor antagonists. J. Med. Chem. 49, 1526–1535 (2006).
- 38. . A study of the allosteric inhibition of HCV RNA-dependent RNA polymerase and implementing virtual screening for the selection of promising dual-site inhibitors with low resistance potential. J. Recept. Sig. Transd. 37(4), 341–354 (2017).
- 39. . Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors. BMC Bioinformatics 13, 1–21 (2012).
- 40. . LigScore: a novel scoring function for predicting binding affinities. J. Mol. Graph. Model. 23, 395–407 (2005).
- 41. . PMF scoring revisited. J. Med. Chem. 49, 5895–5902 (2006).
- 42. Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J. Med. Chem. 51, 7882–7888 (2008).
- 43. . Design, synthesis, and discovery of novel non-peptide inhibitor of caspase-3 using ligand based and structure based virtual screening approach. Bioorg. Med. Chem. 17, 6040–6047 (2009).
- 44. . Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov. Today 15, 444–450 (2010).
- 45. . Comparative pharmacophore development for inhibitors of human and rat 5-α-reductase. J. Mol. Graph. Model. 22, 83–92 (2003).
- 46. . Novel lead generation through hypothetical pharmacophore three-dimensional database searching: discovery of isoflavonoids as nonsteroidal inhibitors of rat 5α-reductase. J. Med. Chem. 44, 3759–3763 (2001).
- 47. . Automated chemical hypothesis generation and database searching with Catalyst®. Perspect. Drug. Discov. 3, 1–20 (1995).
- 48. The stability and dynamics of the human calcitonin amyloid peptide DFNKF. Biophys. J. 87, 146–158 (2004).
- 49. . Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design. Eur. J. Med. Chem. 45, 4409–4417 (2010).
- 50. Synthesis, biological evaluation and in silico studies of new CDK2 inhibitors based on pyrazolo[3,4-d]pyrimidine and pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold with apoptotic activity. J. Enzyme Inhib. Med. Chem. 37(1), 1957–1973 (2022). •• Molecular modeling study was used showing related techniques to the new research in this manuscript.
- 51. Discovery of pyrazolo [3, 4-d] pyrimidine and pyrazolo [4, 3-e][1, 2, 4] triazolo [1, 5-c] pyrimidine derivatives as novel CDK2 inhibitors: synthesis, biological and molecular modeling investigations. RSC Adv. 12(23), 14865–14882 (2022). •• Molecular modeling study was used showing related techniques to the new research in this manuscript.
- 52. Design, synthesis, docking study and anticancer evaluation of new trimethoxyphenyl pyridine derivatives as tubulin inhibitors and apoptosis inducers. RSC Adv. 11(63), 39728–39741 (2021). •• Molecular modeling study was used showing related techniques to the new research in this manuscript.
